The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly Exploratory analysis of the CAPiTA trial

摘要

Objectives: Our objective was to evaluate whether vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) prevents the incidence of community-acquired pneumonia (CAP) caused by influenza (influenza-associated CAP, IA-CAP) or other respiratory viruses in the elderly.